Key result
Targeting the CNP system shows promise for managing long-term essential hypertension with minimal hypotension risk.
Why the study?
Multiple mechanisms contribute to essential hypertension, and targeting the C-type natriuretic peptide system may offer a novel therapeutic approach with minimal risk of hypotension compared to other natriuretic peptides.
Does targeting the C-type natriuretic peptide (CNP) system improve management of essential hypertension?
Does targeting the C-type natriuretic peptide (CNP) system improve management of essential hypertension?
Targeting the C-type natriuretic peptide system is proposed as a potential novel therapeutic strategy for essential hypertension with a low risk of hypotension.
Hypothesis-generating for CNP-targeted hypertension therapies; leaves open the need for randomized trials to confirm benefits and safety.
Multiple mechanisms are involved in essential hypertension. Antihypertensive drugs mainly target increased activity of the sympathetic nervous system, altered production of vasoactive mediators, vascular inflammation, fibrosis, and increased peripheral resistance. C-type natriuretic peptide (CNP) is an endothelium-derived peptide that exerts vascular signaling through two receptors: natriuretic peptide receptor-B (NPR-B) and natriuretic peptide receptor-C (NPR-C). This perspective recapitulates the effects of CNP on the vasculature in relation to essential hypertension. Notably, the risk of hypotension when used as therapy is minimal for the CNP system as compared to its related natriuretic peptides, atrial natriuretic peptide, and B-type natriuretic peptide. As modified CNP is currently being introduced as therapy in congenital growth disorders, we propose that targeting the CNP system either by administering exogenous CNP or altering the endogenous concentrations via inhibition of its degradation may represent an important tool in the pharmacological armory for managing long-term essential hypertension.
No takes yet. Share an insight, caveat, or question.
Perunovic et al. (2023) conducted a review in Essential hypertension. C-type natriuretic peptide (CNP) system targeting was evaluated. Targeting the C-type natriuretic peptide system may represent an important pharmacological tool for managing long-term essential hypertension with minimal risk of hypotension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: